Staphylococcus simulans

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Staphylococcus simulans is a Gram-positive, non-spore-forming, facultatively anaerobic, non-motile, diplococci bacterium. It has been detected in at least 5 gut microbiome compilation studies or metastudies. The DNA G+C content is 34-38%. Staphylococcus simulans is probably a rare gut coloniser. (Schleifer2011Bergey; Kloos1975)



  • This organism has been recovered from human skin, primates, human faeces and clinical sources (urine, wound, vagina - CCUG). The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread (notes: human and animal pathogen; opportunistic in immunocompromised patients). It is an opportunistic pathogen. Is a known gut commensal.
    • GENERAL CHARACTERISTICS (Schleifer2011Bergey); (Kloos1975);
    Character Response
  • Substrates hydrolysed or digested:
  • urea;
  • 🧂
  • Salt tolerance:
  • tolerates 10% salt;
  • 🌡
  • Temperature tolerance:
  • grows at 15℃; grows at 45℃; Grows optimally at 25-40℃.
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; mannose; ribose; lactose; sucrose; trehalose; mannitol; α-methyl glucoside;
  • ⥅
  • Substrates assimilated or utilised:
  • fructose; glucose; glycerol; lactose; mannitol; sucrose;
  • ±
  • Strain-dependent substrate utilisation:
  • galactose; maltose; mannose; ribose; trehalose;
  • Active enzymes:
  • alkaline phosphatase; catalase; β-galactosidase; lipase; pyrrolidine arylamidase; urease;
  • ±
  • Strain-dependent active enzymes:
  • β-glucuronidase; HS nuclease;
    • SPECIAL FEATURES (Schleifer2011Bergey); (Kloos1975);
    Character Response
  • ✓
  • Metabolites produced:
  • lactate;
  • VP test:
  • activity is variable
  • Lysozyme:
  • growth observed
  • ✗
  • Haemolysis:
  • absent
  • ✓
  • Nitrate:
  • reduced
  • ✗
  • Pigments:
  • not produced
    • RESPONSE TO ANTIBIOTICS (Kloos1975); (Goldstein2006b); (Goldstein1999a); (Citron1997);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; ertapenem; imipenem; meropenem; penicillin; piperacillin-tazobactam;
  • ampicillin;
  • Cephalosporins:
  • cefaclor; cefepime; cefoperazone; cefotaxime; cefotetan; cefoxitin; cefpodoxime; cefprozil; cefuroxime;
  • cefixime; ceftazidime;
  • Macrolides:
  • quinupristin-dalfopristin;
  • Tetracyclines:
  • doxycycline; tigecycline;
  • Quinolines:
  • ciprofloxacin; gatifloxacin; levofloxacin; ofloxacin; sparfloxacin; trovafloxacin;
  • Aminoglycosides:
  • streptomycin;
  • Heterocycles:
  • co-trimoxazole; trimethoprim-sulfamethoxazole;
  • Vancomycins:
  • vancomycin; dalbavancin;
  • Miscellaneous antibiotics:
  • daptomycin; linezolid; novobiocin;

  • Macfarlane, S., Furrie, E., Cummings, J. H., & Macfarlane, G. T. (2004). Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 38(12), 1690–1699.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Firmicutes Class:  Bacilli Order:  Bacillales Family:  Staphylococcaceae Genus:  Staphylococcus Gram stain:  + O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Sessile Morphology:  Diplococci Pigment:  neg
    Health:  Unknown
    Source:  human skin, primates, human faeces and clinical sources (urine, wound, vagina - CCUG)
    DNA G+C(%):  34-38
    Opt. T:  25-40℃
    Low T(℃):  15(+)
    High T(℃):  45(+)
    NaCl >6%:  10(+)
    		Aesculin:  neg Urea:  + Gelatin:  neg Casein:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg D-Arabinose:  neg Fructose:  + Galactose:  neg Glucose:  vr Mannose:  + D-Lyxose:  neg Ribose:  d(+) Xylose:  neg Cellubiose:  neg Lactose:  + Maltose:  vr Melezitose:  neg Sucrose:  + Trehalose:  + Turanose:  neg Glycogen:  neg Mannitol:  + Xylitol:  neg Me-α-D-Glc:  + Salicin:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Arabinose:  neg Fructose:  + Fucose:  neg Galactose:  d(ox) Glucose:  + Mannose:  d Rhamnose:  neg Ribose:  d Sorbose:  neg D-Tagatose:  neg Xylose:  neg Cellubiose:  neg Gentiobiose:  neg Lactose:  + Maltose:  d Melezitose:  neg Melibiose:  neg Raffinose:  neg Sucrose:  + D-Turanose:  neg Trehalose:  d Adonitol:  neg D-Arabitol:  neg Dulcitol:  neg Erythritol:  neg Glycerol:  + Inositol:  neg Mannitol:  + Salicin:  neg Sorbitol:  neg Xylitol:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  neg Catalase:  + Urease:  + Coagulase:  neg HS nuclease:  d Ac-β-glcamnd:  neg β-Galactosidase:  + α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  d ArgDH:  vr OrnDC:  neg PyrrolidAA:  + AlkalineP:  + DNAse:  w Lipase:  +
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Lactate:  + Pigment:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  S(MIC50): 0.125, MIC90: 4, RNG: (0.06–8)
    ampicillin:  R(610)
    oxacillin:  Var(MIC50): >2, MIC90: >2, RNG: (≤0.06->2)
    penicillin:  S(MIC50): 8, MIC90: 8, RNG: (0.06–8)
    penicillin_G:  Var
    piper-taz:  S(MIC50): 0.5, MIC90: 16, RNG: (0.125–32)
    ertapenem:  S(0.5/4)
    imipenem:  S(MIC50): 0.03, MIC90: 0.06, RNG: (≤0.007-0.5)
    meropenem:  S(MIC50): 0.125, MIC90: 4, RNG: (0.06–8)
    cefaclor:  S(MIC50): 1, MIC90: 1, RNG: (0.5-2)
    cefepime:  S(MIC50): 1, MIC90: 4, RNG: (0.5-16)
    cefixime:  R(MIC50): 8, MIC90: 16, RNG: (4-16)
    cefoperazone:  S(MIC50): 2, MIC90: 4, RNG: (1-32)
    cefotaxime:  S(MIC50): 2, MIC90: 4, RNG: (1-8)
    cefotetan:  S(MIC50): 16, MIC90: 32, RNG: (8–32)
    cefoxitin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.5–16)
    cefpodoxime:  S(MIC50): 1, MIC90: 2, RNG: (0.5-2)
    cefprozil:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.25-1)
    ceftazidime:  R(MIC50): 8, MIC90: 32, RNG: (8->128)
    cefuroxime:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25-1)
    streptomycin:  SensRNG: (1.6-3.1)
    erythromycin:  Var(MIC50): 0.4-0.8), MIC90: Var(0.4-0.8
    quin-dalf:  S(MIC50): 0.25, MIC90: 0.5, RNG: (≤0.25->8)
    linezolid:  S(MIC50): 1, MIC90: 1, RNG: (0.12-2)
    ciprofloxacin:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.015–16)
    gatifloxacin:  S(MIC50): 0.5, MIC90: 1, RNG: (≤0.03–2)
    levofloxacin:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.015–8)
    ofloxacin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.015–32)
    sparfloxacin:  S(MIC50): 0.5, MIC90: 2, RNG: (≤0.03–4)
    trovafloxacin:  S(MIC50): 0.015, MIC90: 0.03, RNG: (0.015–8)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  S(≤2/4)
    tetracycline:  Var(MIC50): >2, MIC90: >8, RNG: (≤2->8)
    tigecycline:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.03-1)
    dalbavancin:  S(MIC50): 0.125, MIC90: 0.25, RNG: (0.016–2)
    teicoplanin:  Var(MIC50): 2, MIC90: 8, RNG: (≤2->16)
    vancomycin:  S(MIC50): 1, MIC90: 2, RNG: (0.25-4)
    SXT:  S(≤0.5/1)
    co-trimoxazole:  S(MIC50): >1, MIC90: >2, RNG: (≤0.5->2)
    clindamycin:  Var(MIC50): >0.12, MIC90: >8, RNG: (≤0.06->8)
    daptomycin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.06-2)
    novobiocin:  SensRNG: (0.1-0.2)

    References

    SPECIFIC REFERENCES FOR STAPHYLOCOCCUS SIMULANS
  • Schleifer2011Bergey - Bergey's manual of systematic bacteriology. Vol. 3, The Firmicutes. Family Staphylococcaceae, Genus I. Staphylococcus
  • Kloos1975 - Isolation and Characterization of Staphylococci from Human Skin II. Descriptions of Four New Species: Staphylococcus warneri, Staphylococcus capitis, Staphylococcus hominis, and Staphylococcus simulans
  • Goldstein2006b - In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.
  • Goldstein1999a - Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections.
  • Citron1997 - Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR STAPHYLOCOCCUS SIMULANS
  • De2020 - Metagenomic analysis of gut microbiome and resistome of diarrheal fecal samples from Kolkata, India, reveals the core and variable microbiota including signatures of microbial dark matter.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • MacFarlane2004 - Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Woodmansey2004 - Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects.
  • ...............................
    • GENERAL REFERENCES FOR STAPHYLOCOCCUS SIMULANS
  • Ludwig2009 - Revised road map to the phylum Firmicutes.
    • Added: April 08, 2021